SEC	Form	4
-----	------	---

Γ

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

(City)	(State)	(Zip)		
LAKEWAY,	ТХ	78734		
(Street)				Form filed by More than One Reporting Person
C/O ANEBULC 1017 RANCH R		· · · · · · · · · · · · · · · · · · ·	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 04/04/2025	Officer (give title Other (specify below) below)
1. Name and Addres Lin Kenneth		son*	2. Issuer Name and Ticker or Trading Symbol <u>Anebulo Pharmaceuticals, Inc.</u> [ANEB]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner
issuer that is inter	of equity securities of nded to satisfy the se conditions of Rule istruction 10.	the		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

······································	2. Transaction Date (Month/Day/Year)	2A. Deemed     3.       Execution Date, if any     Transaction Code (Instr.       (Month/Day/Year)     8)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
			Code	v		(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	Reported	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (right to buy)	\$1.02	04/04/2025		Α		25,000		(1)	04/03/2035	Common Stock	25,000	\$0	25,000	D	
Stock Option (right to buy)	\$1.02	04/04/2025		Α		4,964		(1)	04/03/2035	Common Stock	4,964	\$0	4,964	D	

### Explanation of Responses:

1. The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders.

#### /s/ Daniel George, as attorney-in-04/07/2025 fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.